Clinical trials: Philadelphia Positive Acute Lymphoblastic Leukemia
Philadelphia Positive, BCR-ABL Positive
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Drug resistance resulting from emergence of Imatinib-resistant BCR-ABL clones is a significant problem in Ph positive ALL patients because after a very good initial response to one TKI inhibitor, many patients relapse within one…
- Conditions
- Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia
- Trial name
- LAL1811 (NCT01641107)
- Testing
- Ponatinib
- Where
- 42 sites in Italy
- Volunteers
- 44 people
- Sponsor
- Incyte Corporation
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome…
- Trial name
- NCT00349518
- Testing
- Dasatinib
- Where
- 20 sites in Hungary, Italy and 4 more
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab.
- Conditions
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
- Trial name
- NCT04722848
- Testing
- Ponatinib + Blinatumomab, Chemotherapy + Imatinib
- Where
- 15 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia, Adult, Ph+ ALL
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed
- Trial name
- Pona-CELL (NCT04554459)
- Testing
- Ponatinib 15 MG Oral Tablet
- Where
- 7 sites in Czechia
- Volunteers
- 4 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Leukemia, Mucositis
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Mucositis, Oral Complications
- Trial name
- UKALL14 (NCT01085617)
- Testing
- palifermin, rituximab, cyclophosphamide
- Sponsor
- University College, London
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual…
- Trial name
- NCT06773936
- Testing
- Induction Phase, Re-Induction Phase, Post-Remission
- Where
- 16 sites in United States
- Volunteers
- 55 people
- Sponsor
- SWOG Cancer Research Network
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2…
- Trial name
- CAMS-Ph+ B-ALL (NCT07152041)
- Testing
- olverembatinib
- Where
- 24 sites in China, Hong Kong
- Volunteers
- 150 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic…
- Trial name
- NCT07074496
- Testing
- ThisCART19A, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few.
- Trial name
- NCT02981784
- Testing
- Ponatinib (Iclusig®), allogeneic stem cell transplantation
- Where
- France
- Volunteers
- 184 people
- Sponsor
- Hospices Civils de Lyon
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia
Study hypothesis: Treatment with dasatinib 100 mg QD is safe and efficacious when given to patients with Ph+ ALL in the post SCT setting.
- Trial name
- DASA-TRAS (NCT01310010)
- Testing
- dasatinib
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Acute Leukemia
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Compared with patients with philadelphia chromosome-negative Acute Lymphoblastic Leukemia (Ph- ALL), patients with Ph-positive (Ph+) ALL exhibit a comparatively poor prognosis.
- Trial name
- NCT05071482
- Testing
- Flumatinib, Imatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
- Trial name
- NCT01670084
- Testing
- nilotinib, rituximab, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases.
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT00351975
- Testing
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.
- Trial name
- NCT00130195
- Testing
- imatinib, cyclophosphamide, daunorubicin
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Japan Adult Leukemia Study Group
Ph+ ALL
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
This is an open-label, prospective clinical cohort study evaluating the efficacy and safety of reduced-intensity chemotherapy combined with targeted therapy and immunotherapy in adult patients with newly diagnosed Philadelphia…
- Trial name
- NCT07493161
- Testing
- Olverembatinib, Venetoclax, Blinatumomab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia…
- Trial name
- NCT07250087
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
The introduction of TKIs has greatly improved the prognosis of Ph+ ALL patients. The third-generation TKI ponatinib in combination with chemotherapy has demonstrated superior efficacy to first- and second-generation TKIs.
- Trial name
- NCT05594784
- Testing
- Olverembatinib, Venetoclax, prednisone
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia
STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia
This proposal, developed in the framework of the GIMEMA, will permit: to evaluate the activity and toxicity of imatinib in the treatment of Ph+ acute lymphoblastic leukemia; to evaluate the molecular response to the treatment…
- Trial name
- NCT00376467
- Testing
- Imatinib
- Where
- 28 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Philadelphia-Negative ALL, Philadelphia-Positive ALL
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the…
- Conditions
- Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT06287528
- Testing
- 19-28z/IL-18 CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center